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Pancreatic destruction affects the majority of patients with cystic fibrosis. We aimed to relate
ultrasound findings to exocrine pancreatic function and cystic fibrosis genotype.
Methods
Patients with cystic fibrosis and a matched group of healthy controls were included. We per-
formed transabdominal ultrasound, and recorded echo intensities of the pancreas and pa-
renchymal characteristics according to endoscopic ultrasound based Rosemont criteria.
Results
We included 39 patients and 29 healthy controls. The cystic fibrosis patients were grouped
according to exocrine pancreatic function; Cystic fibrosis, insufficient (n = 20) and sufficient
(n = 19). Echo intensity measures and visual score demonstrated hyper-echogenicity in the
pancreas insufficient group compared to the pancreas sufficient groups (p<0.001). Ductal
and parenchymal changes were not prevalent in any of the groups.
Conclusion
The hyper-echoic pancreas was the most frequent ultrasonographic finding in exocrine pan-
creas insufficient cystic fibrosis patients. Pancreatic echo levels correlated to
pancreatic phenotype.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in a single large gene
on chromosome 7 encoding the cystic fibrosis transmembrane conductance regulator (CFTR)
protein, a complex chloride channel and regulatory protein found in all exocrine tissues. The
gene was discovered in 1989 and linked the disease to changes in the CFTR-protein [1–3]. The
Cystic Fibrosis Mutation Database lists more than 1900 different mutations in the CFTR gene
[4]. The prevalence in Scandinavian populations is reported to be 1 to 4–5000 live births [5].
Diagnostic criteria for cystic fibrosis are defined in the cystic fibrosis foundation consensus re-
port [6].
Disturbed transport of chloride, sodium and bicarbonate leads to thick, viscous secretions
in various organs, and increased salt content in sweat gland secretions. Patients with cystic fi-
brosis develop pancreatic damage as a result of defective ductal and acinar pancreatic secretion
[7,8]. Population studies indicate that 72–88% of CF patients develop exocrine pancreatic in-
sufficiency [9,10]. The main pathological findings in the pancreas of affected CF are atrophy, fi-
brosis and fatty infiltration [7,11]. Lately, the pancreatic insufficiency prevalence score has
been suggested as a tool to predict pancreatic phenotype from the CF genotype [12,13].
CT and MRI studies of the pancreas in CF patients have demonstrated a signal intense pan-
creas with different patterns of fatty infiltration. (Diffuse fatty replacement, partial fatty re-
placement and pancreatic atrophy). Ductal changes, pancreatic cysts ranging from small to
severe pancreatic cystosis, calcifications and hypoechoic areas representing fibrosis have also
been demonstrated [14–18]. Transabdominal ultrasound is recommended regularly to detect
cystic fibrosis liver disease [19]. Imaging of the pancreas with transabdominal ultrasound is a
widespread and well-documented procedure [20]. Ultrasonography characteristics of the pan-
creas in cystic fibrosis pancreas are described in earlier studies, and the correlation to MRI find-
ings is good [21–23]. Some earlier studies have demonstrated correlation between pancreatic
function and radiological findings in patients with severe exocrine failure [18,23,24]. Neither of
these studies performed assessment of exocrine pancreatic function by faecal elastase or direct
pancreas function testing. In this study, we aim to correlate pancreatic ultrasound characteris-
tics to CF genotype and exocrine pancreatic function assessed by secretin-stimulated endo-
scopic short test [25,26] or faecal elastase [10] in CF patients.
Materials and Methods
Subjects
During a 4 year period (December 2010-May 2014), forty-two consecutive CF patients aged
>15 years attending regular follow up in the CF clinic were offered a detailed evaluation of the
pancreas. The CF diagnosis was evaluated according to the diagnostic criteria for cystic fibrosis
[6]. An age and gender matched group of thirty-two healthy controls was also examined. The
inclusion flow chart is displayed in Fig. 1. Lung-transplanted CF patients and subjects not able
to give informed consent where not included in the study. Subjects with insufficient ultrasono-
graphic visualization of the pancreas were excluded retrospectively. We excluded one CF pa-
tient due to lack of fulfilment of the diagnostic criteria. Further two were excluded due to poor
pancreatic ultrasound visualization during repeated examinations. Three controls had poor ul-
trasonography visualization of the pancreas and were also excluded. We thus present results
from 39 CF patients and 29 healthy controls (HC).
Ultrasound Echo-Intensity of the Pancreas in Cystic Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0121121 March 24, 2015 2 / 12
Competing Interests: The authors have declared
that no competing interests exist.
Ethical considerations
The protocol was approved by the local ethics committee (Regional ethical committee western
Norway. http://www.helseforskning.etikkom.no/. Mail: rek-vest@uib.no) Approval number:
REK: 2010/2857-7) and the study was performed in accordance with the Helsinki Declaration.
All subjects signed an informed consent to participate. The study included subjects from 15
years of age. For patients between 15 and 18 years consent was also signed by parents. The con-
sent forms were approved by the local ethical committee. In the case of use of anonymized
medical images, specific permission was obtained from the participants. Data underlying the
conclusions in the study contain clinical information on humans and publication of the data
material is subject to legal restrictions. A table containing anonymized raw data is published in
the supplements of the article.
Methods
Demographic data and genetics. Patient records were reviewed and patients and controls
were interviewed. Age and sex of the patient, medication, smoking habits, alcohol consump-
tion, body mass index, CFTRmutation status and sweat-test values (Na+ and Cl-) were docu-
mented. Genetic testing was performed using cystic fibrosis v3 Genotyping kit (Thirty-three
CFTRmutations) or Elucigene CF-EU2 kit (Fifty-one mutations). Additional testing was done
for the CFTRmutations 4005+2T>C and R117H. Cystic fibrosis patients with unknown muta-
tion status after screening had whole gene sequencing for known CFTRmutations performed.
Demographic data of the subjects are displayed in Table 1.
Fig 1. Inclusion flow chart. The figure displays the inclusion and exclusion of cystic fibrosis patients and
healthy controls. (CF: Cystic fibrosis. CFI/CFS: Cystic fibrosis insufficient/ sufficient. HC: Healthy controls).
doi:10.1371/journal.pone.0121121.g001
Table 1. Demographic data.
Patients Controls P
CFI (n = 20) CFS (n = 19) HC (n = 29)
Age* 22(15–52) 22 (16–70) 29(18–66)
Gender (♀/♂) 10 / 10 9 / 10 14 / 15
Body mass index 21(20–23) 22(22–26) 22(21–26)
Sweat [Cl-] 110(95–130) 72(67–79) - <0.001
F-Elastase (μg/g) 0.5 (0–14) 565(506–626) - <0.001
D-bicarbonate (meq/L) 13 (10–28) 119(109–127) - <0.001
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Pancreatic insufficiency prevalence (PIP) corresponding to the least severe mutation was
adapted from Ooi et Al [12,13]. Two mutations: 4005 + 2T<C: (3 of 7 PI), and S912x (3 of 3
PI) were not reported from Ooi, and thus calculated from our database. Pancreas insufficiency
prevalence score in patients with only one or no known mutations were defined as zero.
Transabdominal ultrasound. The subjects were fasting>4 hours. A GE Logic E9 scanner
with a 1–5 MHz curvilinear probe was used (GE Medical Systems and Primary Care Diagnos-
tics, Milwaukee, WI, USA). We performed a complete ultrasound scanning with the subjects in
supine position using a transverse or oblique epigastric probe position. The default abdomen
configuration of the scanner was used to acquire the images: Frequency 4.0 MHz, dynamic
range 66, frame rate 15–22 frames per second (varying). Pancreatic head area was traced cover-
ing the area from the pancreatic head to the level of the superior mesenteric artery in the pan-
creatic body. We evaluated ductal and parenchymal changes in the pancreas according to the
endoscopic ultrasound (EUS) list of Rosemont criteria [27]. We also performed echo intensity
(EI) measurements of the liver, pancreas and kidney and a closely related major vessel, using
standard GE built-in software and the GE defined parameter Echo Level. Echo Level measures
the mean intensity of pixels within a user defined area. The scanner utilizes the intensity data
from raw data per pixel and calculates the average. Raw data pixel-measurements imply that
there is no influence of gain, dynamic range or other scanner parameters. EL is measured in dB
and is linear to the intensity [28]. The scale is defined through 255 gray levels reaching from
white (Zero dB = Maximum intensity = Gray Level 255) to black (-99 dB = Minimum
intensity = Gray Level 0)
Region of interest (ROI) was chosen at approximately the same tissue depths in the mea-
sures, avoiding vessels and hyper-echoic areas. Three measures were taken. The ratio between
liver and pancreas echo intensity (LP SIR; liver pancreas signal intensity ratio) and vessel and
pancreas (VP SIR; vessel pancreas signal intensity ratio) were calculated. (LP SIR = EIliver/
EIpancreas, VP SIR = EIvessel/ EIpancreas). (Fig. 2) The median ratio was chosen. A high ratio im-
plicates a bright (Echo intensive) pancreas. We performed a visual score of echogenicity
adapted fromWorthen et Al [29]. Categories 1–4 are defined in Table 2. The score was set indi-
vidually by three operators blinded to exocrine status and CF genotype. Median value was cho-
sen. Discrepancies affecting absolute result were re-scored in consensus between the operators.
Exocrine pancreas function. We assessed exocrine pancreatic function by a secretin-stim-
ulated, short endoscopic function test described elsewhere [25]. Faecal elastase-1 was measured
by a commercial analysis kit (ScheBo Biotech, Giessen, Germany). We classified patients as
exocrine pancreatic sufficient or insufficient by secretin-stimulated bicarbonate concentration
in duodenal juice. Patients with peak bicarbonate concentration<80meq/L were considered
pancreas insufficient. Some cystic fibrosis patients had a dry tap or were unable to perform en-
doscopy. These were classified as insufficient by f-Elastase< 200μg/g.
Statistical analysis
Statistics where calculated in SPSS statistics 22 (IBM SPSS Statistics, New York, USA) and Sig-
maPlot 11, (Copyright 2011 Systat Software Inc., San Jose, CA, USA). Normal distribution of
the samples was tested by Kolmogorov-Smirnov test. We express the results as median values
with range. Simple comparisons between groups were made by student t-tests or Mann-Whit-
ney U-test as appropriate. Correlations were made by Spearman-Rank correlation tests. Accu-
racy data was calculated from receiver operator curves (ROC). Variance is expressed through
95% confidence intervals. 5% level of statistical significance was used. Interobserver reliability
was calculated as intra-class correlation coefficients (ICC) in a random, two-way analysis. The
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scaled, ordinal data were analysed according to consistency. Categorical data were analysed ac-
cording to complete agreement.
Results
Exocrine pancreatic function
When sorted by exocrine pancreatic function, patient groups were divided as follows: Cystic fi-
brosis, pancreatic insufficient (CFI): n = 20; cystic fibrosis pancreatic sufficient (CFS): n = 19.
Data for faecal elastase and bicarbonate are displayed in Table 1.
Pancreas ultrasound
Parenchymal and ductal characteristics. When we evaluated the pancreas according to
criteria in the EUS based Rosemont chronic pancreatitis score, we found no major and only
few minor criteria in our patients. One patient had severe cystic degeneration of the pancreas.
Minor cysts of small diameters (<5mm), calcifications, severe ductal calibre variations were
not seen. No minor or major criteria were detected in the healthy control group. There was
good to excellent visualization of the head and body of pancreas in all the included patients.
Fig 2. Pancreas ultrasonography. The figure is displaying a normal pancreas in pancreas sufficient patient (left) and a typical hyper echoic pancreas in an
insufficient patient (Right). The Visual score graded echogenicity 1 for the left pancreas and 4 for the right pancreas. The image to the right display region of
interest (ROI) for Echo intensity measures (1: Liver, 2: pancreas, 3: Vessel (superior mesenteric vein)).
doi:10.1371/journal.pone.0121121.g002
Table 2. Visual analogue scale (VAS).
Visual analogue scale
Grade 1 Hypo-/ Iso-echogenic compared to liver
Grade 2 Slightly hyper-echogenic compared to liver
Grade 3 Marked hyper-echogenic compared to liver
Grade 4 Severe hyper-echogenic, equals retroperitoneal fat
Table defining the visual analogue scale for signal intensity after Worthen & Al (37).
doi:10.1371/journal.pone.0121121.t002
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Pancreas echo level. The most frequent parenchymal characteristic was a homogenous,
hyperechogenic pancreas (Fig. 2). Calculation of the closely related signal intensity ratios be-
tween liver and pancreas echo levels (LP SIR) and vessel and pancreas echo levels (VP SIR),
both demonstrated significantly higher ratio in the CFI group compared to HC group and CFS
group (p<0.001) (Fig. 3 and Table 3). The same differences were demonstrated by the Visual
analogue score, where CFI group scored higher than CFS and HC group. Fig. 4 displays the
proportion of VAS>2 in the different groups.
Three of the patients in the CFI group and four of the patients in the HC group displaying
hyperechoic pancreas were aged>45 years. We calculated Spearman rank correlations between
age and Echo-level and VAS score. We did not find correlation between age and high echo lev-
els in any of the groups.
Inter-operator agreement considering the VAS score was good with ICC for the average
measures of 0.90 (0.84, 0.93), p<0.001. The agreement for the diagnosis of lipomatosis with a
Fig 3. Liver-pancreas signal intensity ratio. Box plots displaying outliers, 95% confidence intervals,
Interquartile ranges and median values for the liver pancreas signal-intensity ratio in corresponding groups.
(SIR: Signal intensity ratio, CFI/CFS: Cystic fibrosis pancreas insufficient/ sufficient. HC: Healthy controls).
doi:10.1371/journal.pone.0121121.g003
Table 3. Signal-intensity ratios.
Patients Controls P
CFI (n = 20) CFS (n = 19) HC (n = 29)
Liver-pancreas SIR 1.47 (1.36–1.57) 1.19 (1.07–1.37) 1.12 (0.98–1.38) <0.001
Vessel-pancreas SIR 1.76 (1.54–1.92) 1.39 (1.32–1.54) 1.41 (1.37–1.61) <0.001
Table displaying echo intensity ratios. Values are expressed as medians (IQ range). (SIR; Signal intensity ratio).
doi:10.1371/journal.pone.0121121.t003
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cut-off for VAS of<3 as normal, also was good. (ICC for average measures 0.85 (0.78, 0.90),
p<0.001). Inter-agreement between the liver-pancreas echo intensity-measures were excellent
with an ICC for the average measures of 0.98 (0.98, 0.99), p<0.001. Correlation (Spearman
Ranks) between visual score and LP SIR was good. (r = 0.838, p<0.001).
We also performed ROC curves expressing the diagnostic quality of visual score and EL ra-
tios predicting exocrine pancreatic failure. Sensitivity and specificity for the suggested cut-off
for VAS and LP SIR are displayed in Table 4.
Pancreatic size. Tracing of the area of the pancreatic head and body to the level of the of
the superior mesenteric artery displayed smaller pancreas in both CF groups compared to
Healthy controls (p<0.05).
Genotype-phenotype considerations
There was a good correspondence between the predicted pancreas insufficiency prevalence and
exocrine pancreatic function in our material. We also relate our findings of the hyperechoic
pancreas to pancreas insufficiency prevalence. The results are displayed in S2 Table. When di-
vided by our suggested LP SIR cut-off of 1.25, we found that the group displaying the hypere-
choic pancreas has a markedly increased Pancreas insufficiency prevalence score compared to
the non-hyperechogenic group (p<0.001).
Fig 4. Lipomatosis VAS. Fig. displaying the rate of pancreas lipomatosis. White column display all patients
in the groups. Dark columns display the number of subjects scored as VAS3 (CFI/CFS: Cystic fibrosis
pancreas insufficient/ sufficient. HC: Healthy controls).
doi:10.1371/journal.pone.0121121.g004
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Discussion
In this study, we related features of transabdominal ultrasound of the pancreas to exocrine pan-
creatic function and genotype in CF patients. We demonstrated three main findings: First, we
showed a higher pancreatic echogenicity, as a measure of pancreatic lipomatosis in pancreatic
insufficient CF patients compared to pancreatic sufficient patients and healthy controls. Sec-
ondly, the same findings corresponded well to CF genotype and PIP score. Finally, we demon-
strated that the presence of pancreatic lipomatosis in cystic fibrosis patients predicts exocrine
pancreatic insufficiency in CF with an acceptable diagnostic accuracy. We did not demonstrate
other ultrasonographic parenchymal characteristics to be prevalent.
The hyperechoic pancreas or pancreatic lipomatosis in cystic fibrosis estimated by both
MRI and transabdominal ultrasound is described in earlier studies [15,17,18,22]. Relation of
such findings to exocrine pancreatic failure assessed by precise and updated tests for exocrine
pancreatic function is to our knowledge not yet demonstrated.
The study also includes novel considerations of diagnostic accuracy and intra- and inter-ob-
server quality of ultrasound estimated lipomatosis. Pancreatic lipomatosis is a difficult finding
to interpret due to the fact that it is not always related to pancreatic disease. Both age and obesi-
ty have been described factors associated with pancreatic lipomatosis in patients without pan-
creatic disease [29]. This explains the overlap of the phenomenon to the pancreas sufficient
groups. We found more lipomatosis in the higher age group in our pancreas sufficient groups,
but were not able to correlate the grade of lipomatosis to age in neither of the groups. Sub anal-
ysis (not presented) considering only CF patients below the age of 45 years and defining pan-
creatic insufficiency by the combination of both pathological F-elastase and D-bicarbonate
reduces the overlap considerably. The fatty infiltration of the pancreas develops earlier in life in
CF patients with affected pancreatic phenotype than in subjects without CF-induced pancreatic
destruction. The hyperechogenic pancreas seems to predict pancreas affection in the age group
from fifteen to forty five. The prevalence in CF patients younger than fifteen was not explored
in this study.
Cystic fibrosis patients in western Norway were earlier described to have a lower grade of
pancreatic failure than in other regions due to regional variations in genotype with higher prev-
alence of non-classical CF mutations [30]. This fact has given the opportunity to include an ad-
equate number of pancreatic-sufficient cystic fibrosis patients in the study. A number of the
included patients do not have a detected CF mutation. One patient was excluded after revision
of the diagnosis due to weak CF phenotype; the others were included due to the presence of re-
peated positive sweat tests and significant clinical signs of CF.
We chose to use the endoscopic short test to define exocrine pancreatic function. By using
this invasive direct hormonal stimulation test for exocrine insufficiency, we also aimed to de-
tect patients with isolated decreased ductal function, not only end stage pancreatic disease.
Table 4. Accuracy.
Group Sensitivity Specificity Cutoff Accuracy
VAS CF 0.79 (0.54–1.0) 0.88 (0.75–0.96) VAS>2 0.83
LP-SIR CF 0.89 (0.67–0.99) 0.74 (0.49–0.91) 1.25 0.81
VP-SIR CF 0.81 (0.54–0.96) 0.81 (0.54–0.96) 1.54 0.90
Table displaying accuracy data for the ability of predicting pancreatic insufficiency using pancreas hyper echogenicity. Sensitivity and specificity data
expressed as medians and 95% confidence intervals. VAS: Visual analogue scale, LP/VP-SIR: Liver/vessel-pancreas signal intensity ratio. Accuracy:
Area under the curve calculated from receiver-operator curves).
doi:10.1371/journal.pone.0121121.t004
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Using this definition, one more was classified as pancreas insufficient compared to the use of a
combination of faecal elastase and duodenal bicarbonate. This patient was the only CFI patient
below 45 without lipomatosis. A more conservative definition for pancreas insufficiency would
strengthen the overall result.
Echo intensity ratio measures can be influenced by several factors. Setting of the region of
interest, small depth incongruences between the related measures, shadowing from neighbour-
ing organs and liver steatosis are the main factors to consider. Assessing vessel-pancreas ratio
might be a way to exclude the variance in the liver standard due to liver-steatosis. We found
that whether we chose a vessel or the liver as a comparing tissue, the EI-ratios, performed
equally in the assessment of pancreatic lipomatosis. The main explanation of the little influence
of the variations in the reference areas lies in the more pronounced variations in the pancreatic
echo level. We conclude that the variations due to liver steatosis were of minor importance.
The method performed excellent in repeated measures and we did not adjust for or exclude pa-
tients with liver steatosis. Still we recognize that the presence of fatty liver might reduce the
value of the liver as a reference area in the liver-pancreas signal intensity ratio. Increased size of
region of interest and better standardization in the placement of the ROI might improve per-
formance of EI measurements.
Our VAS scale for visual evaluation has been used in earlier studies [29]. We found that
there was a good correlation between EL ratio measures and the visual assessment, and that the
inter-observer reliability was good. We found that estimate of lipomatosis by VAS scale per-
formed largely equal to echo level measurements. Such an analogue scale has its limitations.
We aimed to blind the VAS evaluation to knowledge of diagnosis and exocrine function, but
still observer bias might influence the results.
Classical parenchymal and ductal findings have been demonstrated in MRI studies of the
pancreas in cystic fibrosis patients. In one ultrasonographic study, the presence of small cysts
was noted in 18% of the CF population [22]. Earlier autopsy studies have described the affected
pancreatic tissue in CF consisting of micronoduli or cysts between 1 and 5 millimetres [7]. We
were not able to demonstrate such findings. One explanation might be that if the pancreas is
homogenously dominated by small lesions less than 1 millimetre, this will not present as single
cysts, but rather a generally coarse parenchymal appearance. Cysts between 1 and 3 millimetres
would be difficult to separate from pancreatic ducts. Cysts reaching 4–5 millimetres should
have been detected. We conclude after careful review of the images combined with contrast en-
hanced ultrasound of the pancreas in the same patients (Unpublished data), that this is not a
prevalent feature in our population of CF patients.
We are aware that the Rosemont criteria are validated for endoscopic ultrasound (EUS).
EUS applies higher resolution and closer proximity to the pancreas, and often image more de-
tails than transabdominal ultrasound [27]. The ability to demonstrate minor criteria like
stranding, minor main pancreatic duct calliper variations or dilated pancreatic duct side
branches is limited using transabdominal ultrasonography. However, the visualization of the
pancreas with transabdominal ultrasound in this patient group was excellent, and the detection
of potential major criteria and minor criteria like cysts, hyperechoic foci and severe irregulari-
ties or dilatations of the main pancreatic ducts was demonstrated with fair sensitivity.
An explanation for the low grade of other pancreatic findings than pancreatic lipomatosis
may be the lower prevalence of severe pancreatic genotypes in this study. Nevertheless, the
group includes a sufficient number of classical ΔF508 CF patients with complete exocrine pan-
creatic failure to expect a higher prevalence of such findings if that was the case.
The Pancreas insufficiency prevalence score is a good tool to describe pancreatic genotype-
phenotype relations. We believe that this score can prove to be of substantial aid dealing with
CF patients where the genotype is known to detail. The demonstration of the excellent
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correspondence both to exocrine status and pancreatic ultrasonography findings in our study
underlined the usefulness of the parameter both in science and practical use. The good correla-
tion also underlines our message that pancreatic lipomatosis is a good predictor for pancreatic
disease in CF patients.
Conclusion
We conclude that the demonstration of the hyper echogenic pancreas predicts pancreatic affec-
tion in cystic fibrosis in the age group between fifteen and forty five years with good diagnostic
accuracy. It may be that transabdominal ultrasound demonstrates inferiority to MRI and EUS
regarding complete visualization of the organ, but the possibility of repeated examinations
without radiation risk, the advantage of low costs and the lack of patient discomfort or harm
still makes ultrasonography the most accessible imaging method for regular follow up of
CF patients.
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